New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.

QIAGEN to Aquire STAT-Dx

QIAGEN enters into agreement to acquire STAT-Dx, plans to launch a next-generation, fully integrated multiplex platform for syndromic disease testing in second half 2018 in Europe and later in the U.S.